Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jan 30 · below the Ichimoku cloud · RSI 33 · MACD below its signal · 4% above its 52-week low
| 0.9500 | 52-week high | +236.52% |
| 0.4400 | Previous month high | +55.86% |
| 0.3467 | R3 (classic) | +22.80% |
| 0.3333 | R2 (classic) | +18.08% |
| 0.3200 | Previous day high | +13.35% |
| 0.3200 | Previous week high | +13.35% |
| 0.3200 | Previous month low | +13.35% |
| 0.3067 | R1 (classic) | +8.63% |
| 0.2933 | Pivot | +3.91% |
| 0.2823 | Price now | |
| 0.2800 | Previous day low | −0.81% |
| 0.2800 | Previous week low | −0.81% |
| 0.2700 | 52-week low | −4.36% |
| 0.2667 | S1 (classic) | −5.54% |
| 0.2533 | S2 (classic) | −10.26% |
| 0.2267 | S3 (classic) | −19.71% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $393.7K | 0.00% | 935.12K | −5.3% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a XTNT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Bakewell John KDirector | Stock Award(Grant) at price 0.00 per share. | 215.5K | — |
| Aug 13, 2026 | Lipschultz Tyler PDirector | Stock Award(Grant) at price 0.00 per share. | 215.5K | — |
| Aug 13, 2026 | Browne Sean E.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 550K | — |
| Aug 13, 2026 | Neils Scott CChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 400K | — |
| Aug 13, 2026 | Schallenberger Mark A.Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 450K | — |
| Aug 13, 2026 | Beeson Jonn R.Director | Stock Award(Grant) at price 0.00 per share. | 215.5K | — |
| Aug 13, 2026 | Jain AbhinavDirector | Stock Award(Grant) at price 0.00 per share. | 215.5K | — |
| Aug 13, 2026 | Vizirgianakis Stavros GDirector | Stock Award(Grant) at price 0.00 per share. | 323.3K | — |
| Nov 13, 2025 | Bakewell John KDirector | Stock Award(Grant) at price 0.00 per share. | 158.2K | — |
| Nov 13, 2025 | Bakewell John KDirector | Stock Award(Grant) at price 0.00 per share. | 158.2K | — |
| Nov 13, 2025 | Lipschultz Tyler PDirector | Stock Award(Grant) at price 0.00 per share. | 158.2K | — |
| Nov 13, 2025 | Browne Sean E.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 394.9K | — |
| Nov 13, 2025 | Neils Scott CChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 263.3K | — |
| Nov 13, 2025 | Schallenberger Mark A.Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 292.3K | — |
| Nov 13, 2025 | Beeson Jonn R.Director | Stock Award(Grant) at price 0.00 per share. | 158.2K | — |
| Nov 13, 2025 | Jain AbhinavDirector | Stock Award(Grant) at price 0.00 per share. | 158.2K | — |
| Nov 13, 2025 | Vizirgianakis Stavros GDirector | Stock Award(Grant) at price 0.00 per share. | 553.8K | — |
| Apr 9, 2025 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.42 per share. | 73.11M | $30.71M |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -24.4 | -3.4 | -1.8 | -7.1 | -11.5 | -8.7 | 2.4 | -9.3 | -7.7 | -21.6 | −63.8% | ||
| 2025 | 38.6 | -16.4 | -7.8 | 8.5 | 29.4 | 12.1 | -23.0 | 12.3 | 1.6 | 35.4 | -33.0 | 32.2 | +77.3% |
| 2024 | -18.6 | 19.6 | 6.4 | -23.9 | -19.1 | -12.5 | 15.9 | 1.4 | -8.1 | -19.1 | -27.3 | 10.0 | −61.1% |
| 2023 | 7.6 | 28.2 | -29.7 | -3.1 | 0.0 | 50.0 | 0.0 | 29.0 | -8.3 | 6.4 | 6.0 | -8.9 | +71.2% |
| 2022 | 3.6 | 34.5 | -12.8 | -4.4 | -10.8 | -10.3 | -1.9 | 2.0 | 38.5 | -12.5 | -3.2 | 8.2 | +17.9% |
| 2021 | 22.5 | 194.6 | -45.5 | -22.9 | -19.8 | 11.6 | -24.5 | 2.4 | -11.9 | 3.6 | -39.1 | -20.0 | −53.3% |
| 2020 | -16.2 | 4.5 | -52.1 | 11.9 | 64.0 | -26.8 | 18.9 | -11.2 | -13.7 | 41.5 | 3.4 | 0.0 | −25.0% |
| 2019 | 36.6 | 68.6 | -17.8 | -2.0 | 17.1 | -14.3 | -6.7 | -8.9 | 11.4 | -20.1 | -23.8 | -7.5 | −0.6% |
| 2018 | -14.0 | 16.3 | 15.4 | -11.3 | -18.0 | -3.3 | 3.6 | -18.1 | -18.3 | -17.1 | 2.8 | -50.9 | −76.5% |
| 2017 | -34.5 | 33.3 | 29.2 | -19.4 | 38.0 | -4.3 | 7.6 | 5.6 | -4.0 | -4.2 | -11.6 | -6.6 | +3.6% |
| 2016 | -17.9 | 32.2 | -10.9 | -18.8 | -4.5 | -9.0 | -5.8 | -40.6 | 5.6 | -33.6 | -24.0 | -3.5 | −80.4% |
| 2015 | 8.9 | 8.8 | 14.2 | 2.4 | -2.4 | -14.6 | 0.6 | 6.8 | -13.3 | -3.4 | -12.7 | 1.8 | −7.6% |
| 2014 | 8.0 | 24.1 | 25.4 | -16.7 | -8.6 | 6.2 | 4.7 | -34.0 | -4.7 | -7.1 | -28.4 | 1.7 | −39.4% |
| 2013 | 8.8 | -33.8 | -7.8 | 7.2 | -30.3 | -27.4 | 51.1 | -16.2 | 17.5 | -10.4 | -31.7 | 22.0 | −60.0% |
| 2012 | -0.3 | 3.9 | -18.2 | -15.3 | -28.8 | -8.2 | 17.9 | 4.4 | -6.1 | -11.0 | -10.1 | 0.8 | −56.3% |
| 2011 | -34.1 | -15.2 | -34.7 | 13.5 | 4.8 | -23.0 | -16.2 | -18.9 | 3.6 | 65.5 | -31.7 | 26.5 | −66.4% |
| 2010 | 77.0 | 38.0 | -6.0 | -5.7 | 28.8 | +178.7% |
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.
Buy / hold / sell counts